Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Stock Traders Daily
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

U.S. FDA Approves Baxter International Inc's Intravenous Nutritional Supplement-Reuters


Friday, 4 Oct 2013 12:04pm EDT 

Reuters reported that the U.S. Food and Drug Administration said on October 04, 2013 it has approved Baxter International Inc's nutritional supplement Clinolipid, moving quickly to alleviate a drug shortage. Clinolipid is an injectable source of calories and essential fatty acids designed for adults who cannot eat or drink. It contains a mixture of refined olive and soybean oils. Clinolipid was compared in tests with soybean oil-based lipid emulsions. The agency said the omega-3 to omega-6 fatty acid ratio in Clinolipid has not been shown to improve patient outcomes more than other lipid emulsions. The most common side effects of Clinolipid include nausea and vomiting, excess fat in the blood, high blood sugar, low levels of protein in the blood and abnormal liver function tests. The product is not approved for use in children. 

Company Quote

70.14
0.08 +0.11%
31 Oct 2014